Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Lifshits
Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Cancer Research
Cancer Research
Oncology
Related publications
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
Clinical Cancer Research
Cancer Research
Oncology
P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Development of Covalent Inhibitors That Can Overcome Resistance to First-Generation FGFR Kinase Inhibitors
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors
Cancer Discovery
Oncology
Multiple Mechanisms Contribute to Centriole Separation in C. Elegans
Current Biology
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Neuroscience
Agricultural
A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition
OncoTargets and Therapy
Oncology
Pharmacology
Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Molecular Cancer Therapeutics
Cancer Research
Oncology
